PORT WASHINGTON, N.Y. – January 16, 2018 – Pall Corporation, a global leader in filtration, separation and purification, has been recognized as a 2017 Top 10 Innovator by The Medicine Maker Innovation Awards. The recently launched Cadence inline diafiltration (ILDF) modules were identified as one of the most exciting commercial drug development and manufacturing technologies, tools or services released onto the market in 2017. 

 

Launched in mid-November, the Cadence ILDF modules deliver scalable single-pass diafiltration (DF) for repeated downstream dilution and concentration cycles without a recirculation loop. In addition to enabling fully continuous DF processes in ultrafiltration and DF (UF/DF) processing steps, the modules come in a range of size formats to accommodate various processing volumes and can be used in one or more places in a continuous mAb downstream purification process. 

 

Held annually since 2015, The Medicine Maker Innovation Awards continue to evolve with the industry. To be eligible for the 2017 awards, entries had to be equipment, software, instruments, technology or a service relating to any area of drug development, manufacture and formulation launched between January and December 2017. 

 

“This award comes from our team’s dedication to innovating viable end-to-end integrated continuous bioprocessing solutions, and it is exciting to see the technology recognized,” said Mario Philips, Vice President and General Manager of Pall Life Sciences. “We are honored by the recognition and grateful to our team for their hard work and continued dedication to the effort. With this win, the Cadence portfolio has now been recognized five times by the industry over the past two years.”

 

To learn more about the Cadence ILDF modules, please click here. To start a conversation, please email biopharm@pall.com, or keep up with the Pall Life Sciences division on social media: LinkedInTwitterYouTube

 


About Pall Corporation

Pall Corporation is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The company’s engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation serves customers worldwide.

For more information visit www.pall.com.


Or follow us on social media: Google+ - YouTube -   LinkedIn - Twitter - Facebook


Corporate Media Contact

Pall Corporation

Mariann Kourafas

Director of Communications

+1-508-871-5469

 

Media Contact

White Matter Communications

Beth Willers

bethw@whitemattercomm.com

+1-415-905-0324

 

 

More Biotech lblpress-release
Read all the latest news and developments from Pall and keep in touch with industry trends and opinion.
April 2020
Pall joins a consortium led by Oxford University in fast-tracking clinical trials for a COVID-19 vaccine beginning April 2020.